Atox Bio and Fast-Track Drugs & Biologics Sign an R&D Collaboration Agreement for the Development of Therapeutics for Sepsis and Septic Shock
6/24/2009 9:15:58 AM
JERUSALEM & NORTH POTOMAC, Md.--(BUSINESS WIRE)--Atox Bio Ltd., a subsidiary of Yissum Research Development Company Ltd., and Fast-Track Drugs & Biologics LLC today announced the initiation of a joint R&D program to continue the development of Atox Bio's novel mechanism-based immunomodulator peptide, AB103, for the treatment of sepsis and septic shock. The collaboration includes advanced pre-clinical studies and a Phase I clinical trial to be performed at the University of Maryland, Baltimore, U.S.A. The collaborative R&D program has won the support of the Israel-U.S. Binational Industrial Research and Development Fund (BIRD) for the amount of $575,000.